Hong Jiang, Ph.D.

Peer-Reviewed Articles

1. Nguyen TT, Shin DH, Sohoni S, Singh SK, Rivera-Molina Y, Jiang H, Fan X, Gumin J, Lang FF, Alvarez-Breckenridge C, Godoy-Vitorino F, Zhu L, Zheng WJ, Zhai L, Ladomersky E, Lauing KL, Alonso MM, Wainwright DA, Gomez-Manzano C, Fueyo J. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. J Immunother Cancer 10(7), 2022. PMID: 35902132.
2. Puigdelloses M, Garcia-Moure M, Labiano S, Laspidea V, Gonzalez-Huarriz M, Zalacain M, Marrodan L, Martinez-Velez N, De la Nava D, Ausejo I, Hervás-Stubbs S, Herrador G, Chen Z, Hambardzumyan D, Patino Garcia A, Jiang H, Gomez-Manzano C, Fueyo J, Gállego Pérez-Larraya J, Alonso M. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models. J Immunother Cancer 9(7), 2021. PMID: 34281988.
3. Jiang H, Shin DH, Nguyen TT, Fueyo J, Fan X, Henry V, Carrillo CC, Yi Y, Alonso MM, Collier TL, Yuan Y, Lang FF, Gomez-Manzano C. Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas. Clin Cancer Res 25(22):6801-6814, 2019. e-Pub 2019. PMID: 31455679.
4. Rivera-Molina Y, Jiang H, Fueyo J, Nguyen T, Shin DH, Youssef G, Fan X, Gumin J, Alonso MM, Phadnis S, Lang FF, Gomez-Manzano C. GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory. Neurooncol Adv 1(1):vdz009, 2019. e-Pub 2019. PMID: 31608328.
5. Martínez-Vélez N, Garcia-Moure M, Marigil M, González-Huarriz M, Puigdelloses M, Gallego Pérez-Larraya J, Zalacaín M, Marrodán L, Varela-Guruceaga M, Laspidea V, Aristu JJ, Ramos LI, Tejada-Solís S, Díez-Valle R, Jones C, Mackay A, Martínez-Climent JA, García-Barchino MJ, Raabe E, Monje M, Becher OJ, Junier MP, El-Habr EA, Chneiweiss H, Aldave G, Jiang H, Fueyo J, Patiño-García A, Gomez-Manzano C, Alonso MM. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat Commun 10(1):2235, 2019. e-Pub 2019. PMID: 31138805.
6. Jiang H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, Bover L, Vence LM, Yuan Y, Lang FF, Toniatti C, Hossain MB, Fueyo J. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination. Cancer Res 77(14):3894-3907, 2017. e-Pub 2017. PMID: 28566332.
7. Klein SR, Jiang H, Hossain MB, Fan X, Gumin J, Dong A, Alonso MM, Gomez-Manzano C, Fueyo J. Critical Role of Autophagy in the Processing of Adenovirus Capsid-Incorporated Cancer-Specific Antigens. PLoS One 11(4):e0153814, 2016. e-Pub 2016. PMID: 27093696.
8. Jiang H, Clise-Dwyer K, Ruisaard KE, Fan X, Tian W, Gumin J, Lamfers ML, Kleijn A, Lang FF, Yung WK, Vence LM, Gomez-Manzano C, Fueyo J. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One 9(5):e97407, 2014. e-Pub 2014. PMID: 24827739.
9. Jiang H,* White EJ, Ríos-Vicil CI, Xu J, Gomez-Manzano C, Fueyo J. Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity. J Virol 85(10):4720-9, 2011. e-Pub 2011. PMID: 21367888.
10. Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonso M, White E, Xu J, McDonnell TJ, Shinojima N, Fueyo J. The RB-E2F1 Pathway Regulates Autophagy. Cancer Res 70(20):7882-93, 2010. e-Pub 2010. PMID: 20807803.
11. Piao Y, Jiang H, Alemany R, Krasnykh V, Marini FC, Xu J, Alonso MM, Conrad CA, Aldape KD, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther 16(3):256-65. e-Pub 2008. PMID: 18927600.
12. Alonso MM, Jiang H, Yokoyama T, Xu J, Bekele NB, Lang FF, Kondo S, Gomez-Manzano C, Fueyo J.. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther 16(3):487-493, 2008. e-Pub 2008. PMID: 18253154.
13. Alonso MM, Cascallo M, Gomez-Manzano C, Jiang H, Bekele BN, Perez-Gimenez A, Lang FF, Piao Y, Alemany R, Fueyo J. ICOVIR-5 shows E2F1-addiction and potent anti-glioma effect in vivo. Cancer Res 67(17):8255-8263, 2007. PMID: 17804740.
14. Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F, Xu J, Kondo Y, Bekele BN, Colman H, Lang FF, Fueyo J. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 99(18):1410-4. e-Pub 2007. PMID: 17848677.
15. Olson MV, Johnson DG, Jiang H, Xu J, Alonso MM, Aldape KD, Fuller GN, Bekele BN, Yung WK, Gomez-Manzano C, Fueyo J. Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res 67(9):4005-4007, 2007. PMID: 17483310.
16. Alonso MM, Gomez-Manzano C, Jiang H, Bekele NB, Piao Y, Yung WKA, Alemany R, Fueyo J.. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 14(8):756-761, 2007. e-Pub 2007. PMID: 17557108.
17. Lee OK, Xu J, Fueyo J, Alonso MM, Liu D, Martin V, Jiang H, Piao Y, Liu TJ, Gomez-Manzano C. Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating NIF-1a levels in gliomas. Oncogene 27(9):1310-1314, 2007. e-Pub 2007. PMID: 17704802.
18. Jiang H, Olson MV, Medrano DR, Lee OH, Xu J, Piao Y, Alonso MM, Gomez-Manzano C, Hung MC, Yung WK, Fueyo J. A novel CRM1-dependent nuclear export signal in adenoviral E1A protein regulated by phosphorylation. Faseb J 20:2603-5, 2006. PMID: 17065226.
19. Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res 12(2):556-62, 2006. PMID: 16428500.
20. Guo W, Zhu H, Zhang L, Davis J, Teraishi F, Roth JA, Stephens C, Fueyo J, Jiang H, Conrad C, Fang B. Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models. Cancer Gene Ther 13(1):82-90, 2006. e-Pub 2006. PMID: 16037823.
21. Alonso MM, Fueyo J, Shay JW, Aldape KD, Jiang H, Lee OH, Johnson DG, Xu J, Kondo Y, Kanzawa T, Kyo S, Bekele BN, Zhou X, Nigro J, McDonald JM, Yung WK, Gomez-Manzano C. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J Natl Cancer Inst 97(21):1589-600, 2005. PMID: 16264179.
22. Jiang H, Alemany R, Gomez-Manzano C, Medrano DR, Lemoine MG, Olson MV, Alonso MM, Lee OH, Conrad CC, Yung WK, Fueyo J. Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses. Neoplasia 7(8):723-9, 2005. PMID: 16207474.
23. Jiang H, Gomez-Manzano C, Alemany R, Medrano D, Alonso M, Bekele BN, Lin E, Conrad CC, Yung WK, Fueyo J. Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia 7(1):48-56, 2005. PMID: 15720816.
24. Stolarek R, Gomez-Manzano C, Jiang H, Suttle G, Lemoine MG, Fueyo J. Robust infectivity and replication of Delta-24 adenovirus induce cell death in human medulloblastoma. Cancer Gene Ther 11(11):713-20, 2004. PMID: 15332115.
25. Gomez-Manzano C, Balague C, Alemany R, Lemoine MG, Mitlianga P, Jiang H, Khan A, Alonso M, Lang FF, Conrad CA, Liu TJ, Bekele BN, Yung WK, Fueyo J. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene 23(10):1821-8, 2004. PMID: 15014451.
26. Yang LY, Jiang H, Rangel KM, Plunkett W. Cisplatin-induced ubiquitination of RNA polymerase II large subunit and suppression of induction by 7-hydroxystaurosporine (UCN-01). Oncol Rep 10(5):1489-95, 2003. PMID: 12883729.
27. Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Yung WK, Lang FF. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 95(9):652-60, 2003. PMID: 12734316.
28. Jiang H, Conrad C, Fueyo J, Gomez-Manzano C, Liu TJ. Oncolytic adenoviruses for malignant glioma therapy. Front Biosci 8:d577-88, 2003. PMID: 12700119.
29. Yang LY, Jiang H, Rangel KM. RNA polymerase II stalled on a DNA template during transcription elongation is ubiquitinated and the ubiquitination facilitates displacement of the elongation complex. Int J Oncol 22(3):683-9, 2003. PMID: 12579324.
30. Gomez-Manzano C, Fueyo J, Jiang H, Glass TL, Lee HY, Hu M, Liu JL, Jasti SL, Liu TJ, Conrad CA, Yung WK. Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann Neurol 53(1):109-17, 2003. PMID: 12509854.
31. Yang LY, Li L, Jiang H, Shen Y, Plunkett W. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 6(3):773-81, 2000. PMID: 10741696.
32. Jiang H, Yang LY. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins. Cancer Res 59(18):4529-34, 1999. PMID: 10493501.
33. Jiang H, Feng J, Wang YC. Effect of p21Cip1 gene on the cell cycle regulation of V79-8 cells. Acta Anatomica Sinica 29(3):264-2697, 1998.
34. Jiang H, Feng J, Wang YC. Differential cell cycle regulation between V79 and V79-8 cells. Acta Anatomica Sinica 29(4):387-3896, 1998.
35. Jiang H, Feng J, Wang YC. P21 Cip1 antisense RNA inhibits the differentiation of HL-60 cells induced by all-trans retinoic acid. Progress in Natural Sciences 8(5):513-5205, 1998.
36. Jiang H, Shin DH, Yi Y, Fan X, Gumin J, He J, Gillard AG, Lang FF, Gomez-Manzano C, Fueyo J. Adjuvant therapy with oncolytic adenovirus Delta-24-RGDOX followed localized intratumoral adoptive T-cell therapy promotes antigen spread to sustain systemic antitumor immunity. Cancer Research Communications.

Invited Articles

1. He J, Munir F, Ragoonanan D, Zaky W, Khazal S, Tewari P, Fueyo J, Gomez-Manzano C, Jiang H. Combining CAR T Cell Therapy and Oncolytic Virotherapy for Pediatric Solid Tumors: A Promising Option. Immuno 3(1):37-56, 2023.
2. Nguyen T, Avci NG, Shin DH, Martinez-Velez N, Jiang H. Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses. Cancers (Basel) 10(6), 2018.
3. Klionsky DJ, Abdelmohsen K, Akihisa A, Jiang H, Zughaier SM. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12(1):1-222, 2016. PMID: 26799652.
4. Jiang H, Gomez-Manzano C, Rivera-Molina Y, Lang FF, Conrad CA, Fueyo J.. Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints. Curr Opin Virol. 13:33-39, 2015. PMID: 25863716.
5. Jiang, H, Fueyo, J. Healing after death: antitumor immunity induced by oncolytic adenoviral therapy. OncoImmunology 3(7):e947872, 2014. PMID: 25954598.
6. Klionsky DJ, Abdalla FC, Abeliovich H, Jiang H, Zschocke J, Zuckerbraun B. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8(4):445-544, 2012. PMID: 22966490.
7. Balvers R, Jiang H, Piya S, Gomez-Manzano C, Fueyo J. Adenovirus, Autophagy, and Lysis: Ecstasies and Agonies. Future Virology 6(10):1161-1164, 2011.
8. White EJ, Martin V, Liu JL, Klein SR, Piya S, Gomez-Manzano C, Fueyo J, Jiang H. Autophagy Regulation in Cancer Development and Therapy. Am J Cancer Res 1(3):362-372, 2011.
9. Jiang H, Fueyo J. Eradication of brain tumor stem cells with an oncolytic adenovirus. Discov Med 10(50):24-8, 2010. e-Pub 2010.
10. Jiang H, Martin V, Alonso M, Gomez-Manzano C, Alonso M, Fueyo J. RB-E2F: Molecular rheostat for autophagy and apoptosis. Autophagy 6(8):1216-7, 2010. e-Pub 2010.
11. Jiang H, Gomez-Manzano C, Lang FF, Alemany R, Fueyo J. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr gene Ther 9(5):422-7, 2009. e-Pub 2009.
12. Jiang H, White EJ, Gomez-Manzano C, Fueyo J.. Adenovirus's last trick: You say lysis, we say autophagy. Autophagy 4(1):118-20, 2008. e-Pub 2007. PMID: 18032923.
13. Gomez-Manzano C, Alonso M, Jiang H, Fueyo J. Interspecies adenovirus fiber shows "evolutionary" advantage for oncolytic therapy of gliomas. Cancer Biol Ther 11(7):794-6, 2008. PMID: 18756625.
14. Klionsky DJ, Abeliovich H, Jiang H, Deter RL. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4(2):151-75, 2008. PMID: 18188003.
15. Jiang H, McCormick F, Lang FF, Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticancer Ther 6(5):697-708, 2006. PMID: 16759161.
16. Jiang H, Alonso MM, Gomez-Manzano C, Piao Y, Fueyo J. Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. Expert Rev Anticancer Ther 6(11):1585-92, 2006. PMID: 17134363.
17. Jiang H, Conrad C, Fueyo J, Gomez-Manzano C, Liu TJ.. Oncolytic adenoviruses for malignant glioma therapy. Front Biosci 8:577-588, 2003.
18. Jiang H, Wang YC. Mechanism of cell cycle regulation. Trends in Cell Biology 2(9):1-16, 1998.
19. Jiang H, Wang YC. Research progress in cyclin-dependent kinase inhibitor p21Cip1. Progress in Physiological Science 29(4):339-3418, 1998.
20. Jiang H, Wang YC. Cyclin-dependent kinase inhibitors in mammalian cells. Progress in Physiological Science 27(2):107-112, 1996.

Abstracts

1. Gupta S, Laspidea V, Fueyo J, Zaky W, Becher O, Nguyen TT, Shin DH, Jiang H, Sohoni S, Fan X, Yi Y, Gumin J, Lang FF, Gomez-Manzano C, Alonso MM. Armed oncolytic adenovirus as experimental therapy for pediatric malignant gliomas. The American Society of Pediatric Hematology/Oncology (ASPHO) Annual Meeting 2022, Dec 10-13, 2022 | New Orleans, LA, 2022.
2. Gillard A, Shin DH, Laspidea V, Singh SK, Jiang H, Kim D, Fan X, Yi Y, Lang FF, Alonso MM, Fueyo J, Gomez-Manzano C. Nono is a new adenovirus sensor: implication for virotherapy. Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, Nov 8–12, 2022 | Boston, MA, 2022.
3. Nguyen TT, Shin DH, Kim D, Singh SK, Jiang H, Gillard A, Fan X, Yi Y, Gumin J, Lang FF, Alvarez-Breckenridge C, Alonso MM, Godoy-Vitorino F, Zhai L, Ladomersky E, Lauing KL, Wainwright DA, Fueyo J, Gomez-Manzano C. Examination of the tumor microenvironment of gliomas treated with viroimmunotherapy reveals the production of oncometabolites leading to new therapeutic strategies. Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, Nov 8–12, 2022 | Boston, MA, 2022.
4. Shin DH, Jiang H, Gillard A, Kim D, Nguyen TT, Sohoni S, Fan X, Yi Y, Ban K, Alemany R, Alonso MM, Lang FF, Gomez-Manzano C, Ozpolat B, Fueyo J. Nanoparticle treatment rebalances immunodominance of anti-virus immunity to enhance anti-tumor immunity during oncolytic adenovirus therapy in solid tumors. Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, Nov 8–12, 2022 | Boston, MA, 2022.
5. Shin DH, Jiang H, Ozpolat B, Gillard A, Kim D, Nguyen TT, Alemany R, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Strategies to circumvent the antiviral immunity result in enhanced anti-cancer effect of the oncolytic adenovirus Delta-24-RGD. 14th International Oncolytic Virotherapy Conference (IOVC), Oct 23-26, 2022 | Karuizawa, Nagano, Japan, 2022.
6. Jiang H, Shin DH, Yi Y, Fan X, Gillard A, Gupta S, He J, Alonso MM, Lang FF, Gomez-Manzano C, Fueyo J. Combination of oncolytic adenovirus therapy with adaptive cell therapy enhances systemic anti-tumor immunity. 14th International Oncolytic Virotherapy Conference (IOVC), Oct 23-26, 2022 | Karuizawa, Nagano, Japan, 2022.
7. Jiang H, Shin DH, Sohoni SS, Nguyen TT, Yi Y, Fan X, Gumin J, Singh SK, Lang FF, Gomez-Manzano C, Fueyo J. Sustainable regression of disseminated solid tumors mediated by in situ combinational treatment with adoptive T cell therapy and oncolytic adenovirus Delta-24-RGDOX. Society for Immunotherapy of Cancer (SITC) Annual Meeting, Washington DC, MD, Nov 10-14, 2021, 2021.
8. Sohoni S, Nguyen T, Shin DH, Fan X, Jiang H, Gupta S, Ossimetha A, Yi Y, Bartholomeusz C, Alonso M, Fueyo J, Gomez-Manzano C. Targeting the immunosuppressive microenvironment of metastatic breast cancer with viroimmunotherapy. Proceedings of the AACR: 2021 Annual AACR Meeting, April 10-15; May 17-21, Virtual, 2021.
9. Jiang H, Nguyen T, Shin DH, Sohoni S, Gupta S, Yi Y, Fan X, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus Delta-24-RGDOX collaborates with adoptive T cell therapy to sustain systemic anti-tumor immunity. Proceedings of the AACR: 2021 Annual AACR Meeting, April 10-15; May 17-21, Virtual, 2021.
10. Nguyen T, Shin DH, Jiang H, Wainwright DA, Sohoni S, Gupta S, Ossimetha A, Lang F, Alonso MM, Gomez-Manzano C, Fueyo J. Inhibition of the IDO-Kyn-AhR cascade optimizes virotherapy in glioblastoma and depends on CD4 T-cell activation. Proceedings of the AACR: 2021 Annual AACR Meeting, April 10-15; May 17-21, Virtual, 2021.
11. Gomez-Manzano C, Melendez C, Nguyen T, Ossimetha A, Jiang H, Fueyo J, Godoy-Vitorino F. Gut Microbiome changes are associated with the efficacy of Delta-24-RGDOX viroimmunotherapy against malignant glioma. Proceedings of the AACR: 2021 Annual AACR Meeting, April 10-15; May 17-21, Virtual, 2021.
12. Shin DH, Nguyen TT, Jiang H, Fan X, Yi Y, Sohoni S, Gupta S, Ossimetha A, Gomez-Manzano C, Fueyo J. Evasion of neutralizing antibodies andenhanced anti-tumor effectsof hexon-modified Delta-24-RGD oncolytic adenovirus. Proceedings of the AACR: 2021 Annual AACR Meeting, April 10-15; May 17-21, Virtual, 2021.
13. Gupta S, Laspidea V, Fueyo J, Becher O, Nguyen T, Shin DH, Jiang H, Sohoni S, Fan X, Yi Y, Gumin J, Lang F, Gomez-Manzano C, Alonso MM. Armed Oncolytic virus for treatment of pediatric DIPG. Proceedings of the AACR: 2021 Annual AACR Meeting, April 10-15; May 17-21, Virtual, 2021.
14. Laspidea V, Puigdelloses M, Martinez-Velez N, Garcia-Moure M, Labiano S, Ausejo I, Patiño-García A, Becher OJ, Jiang H, Gupta S, Fueyo J, Gomez-Manzano C, Alonso MM. Oncolytic adenovirus Delta-24-RGD engineered to express 4-1BBl as a therapeutic approach for DIPG. Neuro-Oncol (25th Annual meeting and Education Day of Society for Neuro-oncology; November 18-22, 2020, Virtual) 22(Suppl_2):ii107, 2020.
15. Shin DH, Nguyen T, Jiang H, Sohoni S, Gupta S, Ossimetha A, Alonso M, Gomez-Manzano C, Fueyo J. Hexon swapping mitigates anti-viralimmune responseduring brain tumor virotherapy. Neuro-Oncol (25th Annual meeting and Education Day of Society for Neuro-oncology; November 18-22, 2020, Virtual) 22(Suppl_2):ii95, 2020.
16. Nguyen T, Shin DH, Jiang H, Wainwright D, Sohoni S, Gupta S, Ossimetha A, Lang F, Alonso MM, Fueyo J, Gomez-Manzano C. Delta-24-RGDOX activation of the IDO-Kyn-AhR cascade in glioblastoma: old targets for a new therapy. Neuro-Oncol (25th Annual meeting and Education Day of Society for Neuro-oncology; November 18-22, 2020, Virtual) 22(Suppl_2):ii97, 2020.
17. Jiang H, Shin DH, Nguyen T, Alonso MM, Lang F, Gomez-Manzano C, Fueyo J. Treatment with Delta-24-RGDOX of subcutaneous tumors results in abscopal effect eradicating intracranial melanomas. Neuro-Oncol (24rd Annual Scientific Meeting and Education Day of The Society for Neuro-Oncology; Nov 20-24, Phoenix, AZ) 21(Suppl_6):vi84, 2019.
18. Jiang H, Shin DH, Nguyen T, Lang FF, Gomez-Manzano C, Fueyo J. Systemic immunity against disseminated subcutaneous and intracranial melanomas induced by oncolytic adenovirus Delta-24- RGDOX. J Immunother Cancer. The Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting, November 7-11, Washington, DC 7(Suppl_1):283, 2019.
19. Nguyen N, Shin DH, Jiang H, Lang F, Gomez-Manzano C, Fueyo J. Combined IDO inhibitor and OX40L-armed-oncolytic-adenovirus therapy improves survival in murine glioblastoma. Proceedings of the AACR: Tumor Immunology and Immunotherapy, Nov. 17-20, 2019, Boston, MA, 2019.
20. Rivera-Molina Y, Fueyo J, Jiang H, Nguyen T, Shin DH, Youssef G, Fan X, Gumin J, Alonso MM, Phadnis S, Lang F, Gomez-Manzano C. Activating the immunity within the tumor using viroimmunotherapy: Delta-24-RGD oncolytic adenovirus armed with the immunopositive regulator GITRL. Neuro-Oncol (24rd Annual Scientific Meeting and Education Day of The Society for Neuro-Oncology; Nov 20-24, Phoenix, AZ) 21(Suppl_6):vi87, 2019.
21. Shin DH, Jiang H, Nguyen T, Youssef G, Fan X, Yi Y, Gomez-Manzano C, Fueyo J. Glioblastoma disguised: combined therapy using CD19 expressing oncolytic adenovirus and CD19-targeted CAR T-cells. Proceedings of the AACR: Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy, Jul. 19-22, 2019, San Francisco, CA, 2019.
22. Jiang H, Shin DH, Carrillo C, Henry V, Fan X, Nguyen T, Rivera-Molina Y, Lang FF, Gomez-Manzano C, Fueyo J. Systemic anti-melanoma immunity induced by oncolytic adenovirus Delta-24-RGDOX. Proceedings of the AACR Special Conference: Melanoma: From Biology to Target (January 15-18, 2019; Houston, TX), 2019.
23. Jiang H, Shin DH, Carrillo C, Henry V, Fan X, Nguyen TT, Rivera-Molina Y, Lang F, Gomez-Manzano C, Fueyo J. Localized treatment with oncolytic adenovirus Delta-24-RGDOX elicits efficacious abscopal immunity against disseminated melanomas. J Immunother Cancer. The Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting, November 7-11, Washington, DC 6(Suppl_1):327-328, 2018.
24. Nguyen TT, Rivera-Molina Y, Puerta-Martinez FW, Fan X, Henry V, Jiang H, Lang F, Fueyo J, Gomez-Manzano C. Inflammatory reprogramming of gliomas using Delta-24-RGDOX and imnunometabolic adjuvants. Neuro-Oncology (23rd Annual Scientific Meeting and Education Day of The Society for Neuro-Oncology; Nov 15-18, New Orleans, LA) 20(Suppl_6):vi90-vi91, 2018.
25. Jiang H, Nguyen T, Shin DH, Fan X, Gumin J, Bernatchez C, Lang F, Gomez-Manzano C, Fueyo J. In situ autovaccination mediated by oncolytic adenovirus Delta-24-RGDOX induces efficacious immunity against metastatic melanoma. Neuro-Oncology (23rd Annual Scientific Meeting and Education Day of The Society for Neuro-Oncology; Nov 15-18, New Orleans, LA) 20(Suppl_6):vi91, 2018.
26. Nguyen TT, Rivera-Molina Y, Puerta-Martinez FW, Fan X, Carrillo CC, Henry VK, Jiang H, Lang F, Gomez-Manzano C, Fueyo J. Forced expression of OX40L and inhibition of IDO within the glioblastoma tumor microenvironment creates a potent anti-tumor immune response. J Immunother Cancer. The Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting, November 7-11, Washington, DC 6(Suppl_1):190, 2018.
27. Puerta Martinez F, Yisel A. Rivera Y, Nguyen T, Fan X, Rehnuma S, Hossain MB, Jiang H, Bartholomeusz C, Lang FF, Fueyo J, Gomez-Manzano C. Partial reversion of the tumor immunosuppressed environment by oncolytic adenoviruses armed with positive stimulators of the immune synapis in breast cancer. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Chicago, IL, April 14-18, 2018) 78(Suppl_13), 2018.
28. Hossain MB, Shifat R, Rivera-Molina Y, Francisco Puerta Martinez F, Jiang H, Kim DK, Johnson DG, Bedford MT, Hung M-C, Sulman EP, Lang F, Sawaya R, Fueyo J, Gomez-Manzano C. Histone tyrosine phosphorylation determines glioblastoma cell survival. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Chicago, IL, April 14-18, 2018) 78(Suppl_13), 2018.
29. Hossain M, Shifat R, Rivera-Molina Y, PuertaMartinez F, Jiang H, Kim D, Johnson D, Bedford M, Sulman E, Lang F, Fueyo J, Gomez-Manzano C. TIE2-mediated epigenetic modifications regulate radioresistance of glioblastoma. Neuro-Oncol (22nd Annual Scientific Meeting and Education Day of The Society for Neuro-Oncology; Nov 16-19, San Francisco, CA) 19(Suppl_6):vi96, 2017.
30. Jiang H, Dong A, Carrillo C, Henry V, Fan X, Rivera-Molina Y, Puerta-Martinez F, Nguyen T, Clise-Dwyer K, Lang F, Gomez-Manzano C, Fueyo J. Efficacious anti-melanoma immunity induced by OX40 ligand-expressing oncolytic adenovirus Delta-24-RGDOX. 32nd Annual Meeting of the Society for Immunotherapy of Cancer (National Harbor, MD; Nov. 8-12, 2017), 2017.
31. Rivera-Molina Y, Puerta Martinez F, Nguyen T, Jiang H, Fan X, Shifat R, Hossain MB, Henry VK, Carrillo CC, Gomez-Manzano, Fueyo J. Forced expression of GITRL in cancer cells enhances adenovirus-mediated in situ vaccination. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Washington DC, April 1-5, 2017) 77(Suppl_13):4565, 2017.
32. Puerta Martinez F, Rivera Y, Nguyen T, Fan X, Henderson JM, Rehnuma S, Hossain MB, Jiang H, Fueyo J, Gomez Manzano C. Oncolytic adenoviruses expressing OX40L or GITRL immune modulators show antitumor effect on immune-competent mouse breast cancer models. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Washington DC, April 1-5, 2017) 77(Suppl_13):3668, 2017.
33. Jiang H, Dong A, Rivera-Molina Y, Clise-Dwyer K, Fan X, Puerta Martinez F,Nguyen T, Henry V, Carrillo C, Gomez-Manzano C, Fueyo J. Cancer-killing viruses combined with tumor-targeting immune checkpoint modulation elicits an in situ vaccination effect and expansion of tumor-specific T cells responsible for efficacious systemic anti-cancer activity. Proceedings of the Am. Assoc. Cancer Res. (Annual AACR Meeting, Washington DC, April 1-5, 2017) 77(Suppl_13):3680, 2017.
34. Puerta F, Rivera-Molina Y, Jiang H, Dong A, Fan X, Gomez-Manzano C, Fueyo J. Targeting gliomas and metastatic cancer with oncolytic adenoviruses expressing T-cell activators. DNA Tumor Virus Meeting, McGill Cancer Research Center, Montreal, Quebec, Canada, July 18-23, 2016, 2016.
35. Rivera-Molina Y, Jiang H, Puerta Martinez F, Nguyen T, Fan X, Gomez-Manzano C, Fueyo J. Armed-oncolytic virus Delta-24-GREAT expressing GITRL induces potent anti-glioma effect and specific anti-tumor memory. Tumor Immunology and Immunotherapy, American Association for Cancer Research, Boston, MA, October 20-23, 2016, 2016.
36. Jiang H, Clise-Dwyer K, Bover L, Lang FF, Gomez-Manzano C, Fueyo J. Potentiation of anti-glioma immunity induced by oncolytic adenovirus Delta-24-RGD through viral expression of immune co-stimulator OX40 ligand. J ImmunoTher Cancer. (Society for Immunotherapy of Cancer 30th Annual Meeting, National Harbor, MD; November 4-8, 2015) 3(Suppl_2):337, 2015.
37. Jiang H, Gomez-Manzano C, Clise-Dwyre K, Bover L Vence LM, Lang FF, Conrad CA, Toniatti C, Tufaro F, Fueyo J. Delta-24-RGDOX: Expressing OX40L in gliomas using replication competent oncolytic adenoviruses induces anti-tumor effect and antiglioma immune memory. CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, New York, NY (September 16-19, 2015), 2015.
38. Klein SR, Jiang H, Gomez-Manzano C, Fueyo J. Role of JNK in the regulation of autophagy in adenovirus-infected cancer cells: clinical implications. 2nd Symposium Autophagy- Across Biology and Medicine; April 24, 2015; Houston, TX, 2015.
39. Jiang H, Alonso M, Hossain MB, Gomez-Manzano C, Fueyo J. Delta-24-RGDOX: Targeting OX40/OX40L in brain tumors using oncolytic adenoviruses. Cell Symposia: Cancer, Inflammation, and Immunity; June 14-16, 2015; Sitges, Spain, 2015.
40. Jiang H, Fan X, Clise-Dwyer K, Bover L, Gumin J, Ruisaard KE, Mukheef FJ, Lang FF, Gomez-Manzano C, Fueyo J. Delta-24-RGDOX: making cancer more “visible” to the immune system. Proceedings of the 2015 Annual Meeting of the American Association for Cancer Research (AACR); 2015 Apr 18-22; Philadelphia, PA, 2015.
41. Jiang H, Clise-Dwyer K, Bover L, Lang FF, Yung WKA, Gomez-Manzano C, Fueyo J. Delta-24-RGDOX: an oncolytic adenovirus enhances anti-glioma immunity through expressing the immune checkpoint co-stimulator OX40 ligand. 9th International Conference on Oncolytic Virus Therapeutics; Harvard Medical School, June 13-16, 2015, Boston, MA, 2015.
42. Jiang H, Lang F, Fan X, Gumin J, Bover L, Clise-Dwyer K, Toniatti C, Ruisard K, Conrad C, Vence L, Gomez-Manzano C, Fueyo J. Delta-24-RGDOX: Targeting co-stimulatory immune checkpoints proteins with oncolytic adenoviruses. Neuro-Oncology. 19th Annual Scientific Meeting of the Society for Neuro-Oncology, November 13-16, 2014, Miami, FL 16(Suppl_5):v112, 2014.
43. Cortes-Santiago N, Hossain M, Gabrusiewick K, Fan X, Jiang H, Shifat R, Alonso MM, Fueyo J, Gomez-Manzano C. Counterattacking the force behind glioma invasion. Neuro-Oncology. 19th Annual Scientific Meeting of the Society for Neuro-Oncology, November 13-16, 2014, Miami, FL 16(Suppl_5):v120, 2014.
44. Piya S, Jiang H, Klein SR, Yung WKA, Sawaya R, Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses modulate autophagy in cancer cells via sumoylation of LC3. Proceedings of the 105st Annual Meeting of the American Association for Cancer Research (AACR); 2014 Apr 5-9; San Diego, CA, 2014.
45. Jiang H, Clise-Dwyer K, Fan X, GuminJ, Mukheef F, Bover L, Toniatti C, Ruisard K, Vence L, Yung WKA, Gomez-Manzano C, Fueyo J. Enhancement of anti-tumor immunity induced by OX40 ligand-expressing oncolytic adenovirus Delta-24-RGDOX. NIH/NCI Cancer Immunology and Immunotherapy: Delivering the Promise, October 9-10, 2014, Bethesda, MD, 2014.
46. Jiang H, Klein S, Piya S, Vence L, Yung WKA, Sawaya R, Heimberger A, Conrad C, Lang F, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus Delta-24-RGD infection activates T-cell immune response against glioma cells. Neuro-Oncology (4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 2013 Scientific Meeting and Education Day of the Society for Neuro-Oncology, November 21-24, 2013, San Francisco, CA) 15(Suppl_3):iii63-iii64, 2013.
47. Jiang H, White E, Rios-Vicil CI, Yung WKA, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus Delta-24-RGD induces cell lysis through autophagy and autophagy-triggered caspcase activation. Neuro-Oncology (16th Annual Scientific Meeting of the Society for Neuro-Oncology & AANS/CNS Section on Tumors, November 17-20, 2011, Orange County, CA) 13:iii116, 2011.
48. Piya S, White E, Klein S, Jiang H, Lang F, Yung WKA, Gomez-Manzano C, Fueyo J.. Delta-24-RGD modulates autophagy in glioma cells by activation of the Beclin1/PI3KC complexes. Neuro-Oncology (16th Annual Scientific Meeting of the Society for Neuro-Oncology & AANS/CNS Section on Tumors, November 17-20, 2011, Orange County, CA) 13:iii70, 2011.
49. Piya S, White EJ, Jiang H, Klein S, McDonnell TJ, Yung WKA, Gomez-Manzano C, Fueyo J. The oncoprotein E1B19K is part of the Beclin 1 interactome in adenovirus-infected cells. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL: AACR, 2011.
50. Klein SR, Piya S, White EJ, Jiang H, Yung WKA, Gomez-Manzano C, Fueyo J.. JNK1-phosphorylation of Bcl-2 is essential for adenoviral-induced autophagic cell death in glioma cells. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL: AACR, 2011.
51. Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonso M, White Em Xu J, McDonnell TJ, Shinojima N, Fueyo J. RB/E2F: gatekeepers of autophagy and apoptosis in glioma cells. 15th Annual Meeting of the Society of Neuro-Oncology (SNO), #CB-69, platform presentation, 2010.
52. Alonso M, Gomez-Manzano C, Vaillant B, Xu J, Liu D, Jiang H, White EJ, Colman H, Fueyo J. Salinomycin displays more potent anticancer effect against brain tumor stem cells than temozolomide. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR, 2010.
53. Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonso M, White EJ, Xu J, McDonnell TJ, Shinojima N, Fueyo J. RB/E2F1 in the crossroads of autophagy and apoptosis. In: Proceedings of the 101st Annual Meeting of the Americal Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR, 2010.
54. Liu D, Fueyo J, Martin V, Xu J, Cortes-Santiago N, Jiang H, White E, Gomez-Manzano C. Tie2/TEK Modulates the Interaction of Glioma Cells with Tumor Microenvironment. 20th Annual Meeting of the European Neurological Society, 2010.
55. White EJ, Jiang H, Xu J, Gomez-Manzano C, Fueyo J. Involvement of autophagy in oncolysis: E1A is required but not sufficient. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR;, 2009.
56. Jiang H, White E, Gumá S, Ji Y, Gomez-Manzano C, Conrad CA, Fueyo J. Enhanced oncolysis of glioma cells by Delta-24-RGD combining with 2-deoxyglucose through autophagic cell death. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR;, 2009.
57. Jiang H, Xu X, Lang F, Colman H, Gomez-Manzano C, Bogler O, Latha K, Yung WKA, Fueyo J. Delta-24-RGD induces autophagy in brain tumor stem cells and prolongs survival in glioma-bearing mice. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA, 2008.
58. Alonso M, Gomez-Manzano C, Jiang H, Martin V, Liu D, Xu J, Yung WKA, Gilbert M, Fueyo J. Role of the silencing of the MGMT promoter in the therapeutic synergy between Delta-24-RGD and temozolomide. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA, 2008.
59. White E, Jiang H, Alonso M, Piao Y, Xu J, Conrad C, Yung WKA, Gomez-Manzano C, Fueyo J. Atg5 is required for adenovirus-induced autophagy in cancer cells. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA, 2008.
60. Jiang H, Gomez-Manzano C, Yokoyama T, Alonso MM, Kondo S, Xu J, Bekele BN, Colman H, Lang FF, Fueyo J.. Oncolytic adenovirus Delta-24-RGD induces efficacious antiglioma activity in brain tumor stem cell models. 12th Annual Meeting of the Society for Neuro-Oncology (SNO), In: Neuro Oncol, 2007.
61. Piao Y, Jiang H, Xu J, Alonso M, Lee OH, Conrad C, Yung WKA, Gomez-Manzano C, Fueyo J. Delta24-RIVER oncolytic adenovirus: targeting mutant EGFR glioma cells. 98th AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA, 2007.
62. Alonso MM, Gomez-Manzano C, Lee OH, Jiang H, Piao Y, Alemany R, Lang F, Yung WKA, Fueyo J.. Oncolytic strategies to target brain tumor stem cells and overcome MGMT-mediated temozolomide resistance. 59th Annual Symposium on Cancer Research, 2006.
63. Jiang H, Aoki H, Lee OH, Kondo S, Lang F, Yung WKA, Colman H, Gomez-Manzano C, Fueyo J.. Cancer stem cells undergo autophagy after infection with oncolytic adenoviruses. 59th Annual Symposium on Cancer Research, 2006.
64. Piao Y, Jiang H, Xu J, Ji YJ, Gomez-Manzano C, Conrad C, Fueyo J.. Targeting mutant EGF receptor for glioma therapy using oncolytic adenoviruses. 10th Annual Trainee Recognition Day & Research Exposition, 2006.
65. Jiang H, Olson MV, Xu J, Lee OH, Piao Y, Yung WKA, Fueyo J.. Exportin 1-mediated nuclear export of adenovirus E1A protin: A novel target for generation of oncolytic viruses. Proc Amer Assoc Cancer Res 47:702-a, 2006.
66. Olson MV, Johnson DG, Aldape K, Fuller GN, Jiang H, Alonso MM, Yung WKA, Guha A, Gomez-Manzano C, Fueyo J.. Transgenic mouse model provides the first direct evidence supporting the oncogenic role of E2F1 in brain. Proc Amer Assoc Cancer Res 47:643, 2006.
67. Olson M, Jiang H, Medrano D, Gomez-Manzano C, Aldape K, Fueyo J. GFAP-E2F1 transgenic mouse provides the first evidence of an oncogenic role of E2F1 in brain tumor formation. Keystone Conferences: Cellular Senescence and Cell Death, Keystone, Colorado, 2005.
68. Olson M, Medrano D, Jiang H, Gomez-Manzano C, Alonso M, Aldape K, Price R, Yung WKA, Fueyo J. Developmental abnormalities and oncogenesis in the brain of a transgenic E2F1 mouse model. Neuro-Oncology 7:289, 2005.
69. Alonso M, Alemany R, Gomez-Manzano C, Yung WKA, Jiang H, Fueyo J. Oncolytic adenovirus Icovir-2 shows improved therapeutic index than D24-RGD for glioma. 96th annual meeting AACR, Anaheim, 2005.
70. Alonso M, Alemany R, Gomez-Manzano C, Yung WKA, Jiang H, Fueyo J. Icovir-2, an old friend with a new face: E2F-1 mediated glioma selectivity for Delta24-RGD. Neuro-Oncology 7:377, 2005.
71. Jiang H, Medrano D, Gomez-Manzano C, Lemoine M, Alemany R, Olson M, Alonso M, Conrad C, Yung WKA, Fueyo J. Downmodulation of E1A Protein Expression as a Novel Strategy to Design Cancer Selective Adenoviruses. 96th annual meeting AACR, Anaheim, 2005.
72. Olson MV, Alonso M, Medrano D, Sheng X, Gomez-Manzano C, Jiang H, Yung WKA, Fueyo J. E2F1 transcriptionally activates PTEN. 96th annual meeting AACR, Anaheim, 2005.
73. Jiang H, Alemany R, Gomez-Manzano C, Yung WK, Sawaya R, Lang FF, Fueyo J. Comparison of the Antiglioma Effect of E1A and E1B-55kD-Mutant Oncolytic Adenoviruses. [Oral Presentation] 2004 AANS/CNS Section on tumors Sixth Biennal Sattelite Symposium, San Francisco, 2004.
74. Medrano D, Jiang H, Gomez-Manzano C, Olson M, Lemoine M, Yung WKA, Fueyo J. Replication-competent adenoviruses with impaired p300/CBP binding express low E1A protein levels: implications for oncolytic therapy. 8th Annual trainee recognition day and research exposition. UTMDACC, Houston, 2004.
75. Medrano D, Jiang H, Johnson DG, Aldape K, Olson M, Gomez-Manzano C, Fueyo J. Transgenic overexpression of E2F1 in the brain in E2F4 null background results in severe hydrocephalus similar to E2F5 null mice. Special AACR Conference on Cell Cycle and Cancer: Pathways and Therapies, Fort Lauderdale, Florida, 2004.
76. Alonso MM, Gomez-Manzano C, Aldape K, Jiang H, Xu J, Kondo Y, Fueyo J. E2F1 upregulates telomerase: cell-cycle related telomerase activity in sarcoma cells. 95th. Annual Meeting, American Association for Cancer Research, Orlando, FL, 2004.
77. Jiang H, Gomez-Manzano C, Medrano D, Cass A, Alonso M, Alemany R, Yung WKA, Fueyo J. The level of E1A as a factor for tumor selectivity in oncolytic adenoviruses. 95th. Annual Meeting, American Association for Cancer Research, Orlando, FL, 2004.
78. Jiang H, Medrano D, Gomez-Manzano C, Courmier F, Yung WKA, Fueyo J. Replication competent adenoviruses with impaired p300/CBP binding express low E1A proteins levels: implication for oncolytic therapy. Neuro-Oncology 5:301-302, 2003.
79. Gomez-Manzano C, Jiang H, Stolarek R, Lang FF, Yung WK, Fuller GN, Fueyo J. U-87 MG Animal Model: predictability of growth kinetics and its use in oncolytic therapy for gliomas. Special AACR meeting, Orlando, FL, 2003.
80. Fueyo J, Gomez-Manzano C, Alemany R, Lemoine MG, Stolarek R, Jasti S , Courmier F, Jiang H, Lamfers M, Dirven C, Curiel DT, Yung WK. Oncolytic adenoviruses for gliomas therapy. 5th Congress of the European Association for Neuro-Oncology. Florence, Italy, 2002.
81. Fueyo J, Gomez-Manzano C, Jiang H, Lemoine M, Stolarek R, Courmier F, Jasti S, Conrad C, Yung WKA. Oncolytic adenoviruses, CPT-11, and topoisomerase I: Mechanisms underlying chemosensitization. Neuro-Oncology 4:322, 2002.

Book Chapters

1. Gomez-Manzano C, Jiang H, Alonso MM, Yung WKA, Fueyo J.. Gene Therapy. In: Neuro-Oncology. In series: Handbook of Clinical Neurology. 3rd ed. Elsevier: Edinburgh, UK, 331-8, 2012.
2. Jiang H, Fueyo J. Gene therapy of brain tumors. In: Gene-based Therapies for Cancer. Springer Science + Business Media and Humana Press Inc, 17-32, 2010.
3. Jiang H, White EJ, Conrad C, Gomez-Manzano C, Fueyo J. Autophagy pathways in glioblastoma. In: Methods in Enzymology: Autophagy in Disease and Clinical Applications. Part C. Academic Press, 273-86, 2009.
4. Alonso MM, Gomez-Manzano C, Alemany R, Jiang H, McCormick F, Fueyo J.. Conditionally replicative adenoviruses as antitumoral agents: Past, present and future. In: Cancer and Gene Therapy. Transworld Research Network: Kerala, India, 41-54, 2007.
5. Jiang H, McCormick F, Gomez-Manzano C, Curiel DT, Lang FF, Yung WKA, Fueyo J. Replicating viruses for brain tumor treatment. In: Gene Therapy for Neurological Disorders. Taylor and Francis Group: New York, NY, 293-326, 2006.
6. Stolarek R, Fueyo J, Gomez-Manzano C, Jiang H, Yung WKA. Gene Therapy for Gliomas: Targeting the Cancer Genome. In: Genomic and Molecular Neuro-Oncology. In series: Molecular Oncology and Cancer Genomics. Jones and Bartlett Publishers: Sudbury, MA, 281-302, 2003.

Books (edited and written)

1. Jiang H, Li R.. Reforming of Life. In: An Introduction to Genetic Engineering. Hainan Publishing House: China, 1993.